2011769-21-2

DSM421 is a dihydroorotate Dehydrogenase Inhibitor (DHODH) with Improved Drug-like Properties for Treatment and Prevention of Malaria. SM421 showed equal activity against both P. falciparum and P. vivax field isolates. DSM421 has the potential to be developed as a single-dose cure or once-weekly chemopreventative for both P. falciparum and P. vivax malaria, leading to its advancement as a preclinical development candidate.